Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin

[1]  R. Evers,et al.  Interindividual Variability in Hepatic Organic Anion-Transporting Polypeptides and P-Glycoprotein (ABCB1) Protein Expression: Quantification by Liquid Chromatography Tandem Mass Spectroscopy and Influence of Genotype, Age, and Sex , 2014, Drug Metabolism and Disposition.

[2]  P. Ridker,et al.  Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol Reduction: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial , 2012, Circulation. Cardiovascular genetics.

[3]  M. Jamei,et al.  A Mechanistic Framework for In Vitro–In Vivo Extrapolation of Liver Membrane Transporters: Prediction of Drug–Drug Interaction Between Rosuvastatin and Cyclosporine , 2013, Clinical Pharmacokinetics.

[4]  Michael Frankfurter,et al.  Water Resources Systems Planning And Management , 2016 .

[5]  Sebastian Polak,et al.  Population-Based Mechanistic Prediction of Oral Drug Absorption , 2009, The AAPS Journal.

[6]  P. Neuvonen,et al.  Global analysis of genetic variation in SLCO1B1. , 2008, Pharmacogenomics.

[7]  R. Weaver,et al.  ATP-dependent transport of statins by human and rat MRP2/Mrp2. , 2013, Toxicology and applied pharmacology.

[8]  K. Verhoeckx,et al.  Drug-Drug Interactions between Rosuvastatin and Oral Antidiabetic Drugs Occurring at the Level of OATP1B1 , 2013, Drug Metabolism and Disposition.

[9]  Bradley L Urquhart,et al.  Human Skeletal Muscle Drug Transporters Determine Local Exposure and Toxicity of Statins , 2010, Circulation research.

[10]  K. To,et al.  The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins , 2011, Expert opinion on drug metabolism & toxicology.

[11]  M. Farmen,et al.  Genetic Variation in Metabolizing Enzyme and Transporter Genes: Comprehensive Assessment in 3 Major East Asian Subpopulations With Comparison to Caucasians and Africans , 2010, Journal of clinical pharmacology.

[12]  A. Nafziger,et al.  Evaluation of inhibitory drug interactions during drug development: Genetic polymorphisms must be considered , 2005, Clinical pharmacology and therapeutics.

[13]  P. Neuvonen,et al.  High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). , 2004, Pharmacogenetics.

[14]  P. Neuvonen,et al.  Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2007, Clinical pharmacology and therapeutics.

[15]  Nathan D. Pfeifer,et al.  Hepatic Basolateral Efflux Contributes Significantly to Rosuvastatin Disposition I: Characterization of Basolateral Versus Biliary Clearance Using a Novel Protocol in Sandwich-Cultured Hepatocytes , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[16]  R. Collins,et al.  SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.

[17]  P. Neuvonen,et al.  Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake , 2011, Pharmacological Reviews.

[18]  N. Fukuda,et al.  Pharmacokinetic/pharmacodynamic modeling and simulation of rosuvastatin using an extension of the indirect response model by incorporating a circadian rhythm. , 2010, Biological & pharmaceutical bulletin.

[19]  H. Wortelboer,et al.  Combined Analysis of Pharmacokinetic and Efficacy Data of Preclinical Studies with Statins Markedly Improves Translation of Drug Efficacy to Human Trials , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[20]  Hugh A. Barton,et al.  Mechanistic Pharmacokinetic Modeling for the Prediction of Transporter-Mediated Disposition in Humans from Sandwich Culture Human Hepatocyte Data , 2012, Drug Metabolism and Disposition.

[21]  M Rowland,et al.  Best Practice in the Use of Physiologically Based Pharmacokinetic Modeling and Simulation to Address Clinical Pharmacology Regulatory Questions , 2012, Clinical pharmacology and therapeutics.

[22]  Margaret Nichols.  Trans , 2015, De-centering queer theory.

[23]  Caroline A. Lee,et al.  Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment , 2005, Clinical pharmacology and therapeutics.

[24]  H. Zimdahl,et al.  International Transporter Consortium Commentary on Clinically Important Transporter Polymorphisms , 2013, Clinical pharmacology and therapeutics.

[25]  A. Rostami-Hodjegan.  Response to “The Link Between Pharmacodynamics and Physiologically Based Pharmacokinetic Models” , 2013, Clinical pharmacology and therapeutics.

[26]  Paul D. Martin,et al.  Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. , 2002, British journal of clinical pharmacology.

[27]  Kazuya Maeda,et al.  Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans , 2009, Journal of Pharmacology and Experimental Therapeutics.

[28]  M. Rowland,et al.  Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. , 2006, Journal of pharmaceutical sciences.

[29]  R. Kim,et al.  Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. , 2006, Gastroenterology.

[30]  M. Niemi.  Transporter Pharmacogenetics and Statin Toxicity , 2010, Clinical pharmacology and therapeutics.

[31]  R. Davidson,et al.  Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. , 2001, The American journal of cardiology.

[32]  Yi Wang,et al.  Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin , 2008, Drug Metabolism and Disposition.

[33]  J. Barrish,et al.  (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with reduced myotoxicity potential. , 2008, Journal of medicinal chemistry.

[34]  P. Ridker,et al.  Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial , 2015, Circulation.

[35]  Meng Li,et al.  Identification of interspecies difference in efflux transporters of hepatocytes from dog, rat, monkey and human. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[36]  J. Paulauskis,et al.  An association study of 43 SNPs in 16 candidate genes with atorvastatin response , 2005, The Pharmacogenomics Journal.

[37]  L. Puccetti,et al.  Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. , 2010, Atherosclerosis.

[38]  I. Roots,et al.  Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations , 2008, European Journal of Clinical Pharmacology.

[39]  G Levy,et al.  Predicting Effective Drug Concentrations for Individual Patients , 1998, Clinical pharmacokinetics.

[40]  P. Neuvonen,et al.  Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population , 2006, European Journal of Clinical Pharmacology.

[41]  G. Holdgate,et al.  Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. , 2003, Biochemical Society transactions.

[42]  G. Ginsburg,et al.  The SLCO1B1*5 genetic variant is associated with statin-induced side effects. , 2009, Journal of the American College of Cardiology.

[43]  P. Neuvonen,et al.  Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate , 2008, Pharmacogenetics and genomics.

[44]  L Zhang,et al.  Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review , 2011, Clinical pharmacology and therapeutics.

[45]  H. Kusuhara,et al.  Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. , 2004, Drug metabolism and pharmacokinetics.

[46]  A. Forrest,et al.  The Link Between Pharmacodynamics and Physiologically Based Pharmacokinetic Models , 2013, Clinical pharmacology and therapeutics.

[47]  Kathryn E. Kenworthy,et al.  Understanding the interplay of drug transporters involved in the disposition of rosuvastatin in the isolated perfused rat liver using a physiologically-based pharmacokinetic model , 2012, Xenobiotica; the fate of foreign compounds in biological systems.

[48]  Jery R. Stedinger,et al.  Water Resources Systems Planning And Management , 2006 .

[49]  N. Samani,et al.  Hepatic Metabolism and Transporter Gene Variants Enhance Response to Rosuvastatin in Patients With Acute Myocardial Infarction: The GEOSTAT-1 Study , 2010, Circulation. Cardiovascular genetics.